^
Association details:
| Biomarker: | FGFR3 fusion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | vofatamab (B-701) (FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).
Published date:
05/16/2018
Excerpt:
B-701 combined with standard dose D in an every 3 week schedule in patients with mUCC was well-tolerated with expected myelosuppression. Enhanced activity was seen in the FGFR3 M/F compared to WT patients
Secondary therapy:
docetaxel
DOI:
10.1200/JCO.2018.36.15_suppl.4534
Trial ID:
